IMPROVED COMPOSITIONS AND METHODS FOR CHEMODENERVATION USING NEUROTOXINS
    1.
    发明授权
    IMPROVED COMPOSITIONS AND METHODS FOR CHEMODENERVATION USING NEUROTOXINS 失效
    FOR化学去神经改良的组合物和方法与NEURO毒素

    公开(公告)号:EP0773788B1

    公开(公告)日:2003-05-07

    申请号:EP96917968.8

    申请日:1996-06-04

    申请人: Pearce, L. Bruce

    IPC分类号: A61K38/16 A61P21/02 A61P25/00

    摘要: The compositions and methods disclosed herein utilize admixtures of neurotoxins to cause denervation which is unexpectedly more localized and of longer duration than otherwise occurs with single neurotoxins. The compositions and methods of the invention utilize neurotoxin admixtures calibrated in median paralysis units rather than LD50s. Admixtures of neurotoxins include, but are not limited to, the botulinum serotypes A-G and tetanus toxin. The clinical benefits of the disclosed invention include: lengthening intervals between neurotoxin treatments; reducing adverse immunogenic responses to neurotoxins; and, reducing adverse diffusion-dependent side-effects of neurotoxin treatments.

    IMPROVED COMPOSITIONS AND METHODS FOR CHEMODENERVATION USING NEUROTOXINS
    2.
    发明公开
    IMPROVED COMPOSITIONS AND METHODS FOR CHEMODENERVATION USING NEUROTOXINS 失效
    FOR CHEMODENERVIERUNG改进的组合物和方法与NEURO毒素

    公开(公告)号:EP0773788A1

    公开(公告)日:1997-05-21

    申请号:EP96917968.0

    申请日:1996-06-04

    申请人: Pearce, L. Bruce

    发明人: Pearce, L. Bruce

    IPC分类号: A61K38

    摘要: The compositions and methods disclosed herein utilize admixtures of neurotoxins to cause denervation which is unexpectedly more localized and of longer duration than otherwise occurs with single neurotoxins. The compositions and methods of the invention utilize neurotoxin admixtures calibrated in median paralysis units rather than LD50s. Admixtures of neurotoxins include, but are not limited to, the botulinum serotypes A-G and tetanus toxin. The clinical benefits of the disclosed invention include: lengthening intervals between neurotoxin treatments; reducing adverse immunogenic responses to neurotoxins; and, reducing adverse diffusion-dependent side-effects of neurotoxin treatments.